Evaluation of the first-in-class antitumor metabolite agent CPI-613 in hematologic malignancies

Timothy S. Pardey MD, PhD1,2,3, Laura M. DeFord-Watts PhD2, Erica Peronto BS1, Denise Levitan MD1,3, David Hurd MD1,3, Steven Kridel PhD2,3, Robin Harrelson BSN1,3, Megan Manuel MSN1,3, Susan Lyeter PA-C1,3 and Bayard Powell1,3

1Department of Internal Medicine, Section on Hematology, Wake Forest School of Medicine, Winston-Salem, NC; 2Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC; 3Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC

CPI-613 is a Novel Liposate Derivative

CPI-613 is Effective Against Several Adverse Prognostic Markers

CPI-613 in AML

CPI-613 Has Activity in Burkitt's Lymphoma, Patient #14

CPI-613 Has Activity in AML, Patient #4

CPI-613 Clinical Activity Summary

Conclusions

We gratefully acknowledge support from: Cerebrosphere Pharmaceuticals, The Doug Clay Foundation for Leukemia Research, The MacKay Foundation for Cancer Research, and The F. Panter Turner.